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Abstract 1 
Introduction 2 
Teriparatide stimulates bone formation and resorption and therefore can cause bone gain and 3 
loss.  We simultaneously characterised the central and peripheral skeleton using imaging 4 
techniques to better understand the mechanism of action of teriparatide.  5 
 6 
Methods 7 
Postmenopausal, osteoporotic women (n=20, 65.4±5.5 years) were recruited into a 104-week 8 
study of teriparatide.  Imaging techniques included DXA, quantitative computed tomography 9 
(QCT) and high-resolution peripheral quantitative computed tomography (HR-pQCT). 10 
 11 
Results 12 
Total lumbar spine areal bone mineral content (aBMC) (+11.2%), total lumbar spine areal bone 13 
mineral density (aBMD) (+8.1%), sub-regional thoracic spine aBMD (+7.5%), lumbar spine 14 
aBMC (+23.5%), lumbar spine aBMD (+11.9%), pelvis aBMC (+9.3%) and pelvis aBMD 15 
(+4.3%) increased.  However, skull aBMC (-5.0%), arms aBMC (-5.1%), legs aBMC (-2.9%) 16 
and legs aBMD (-2.5%) decreased.  Overall, we did not observe a change in total body bone 17 
mineral. 18 
Increases in L1-L3 volumetric BMD (vBMD) (+28.5%) occurred but there was no change in 19 
total proximal femur vBMD. 20 
Radius and tibia cortical vBMD (-3.3% and -3.4%) and tissue mineral density (-3.2% and -21 
3.8%) decreased and there was an increase in porosity (+21.2% and +10.3%). Tibia, but not 22 
radius, WUDEHFXODU LQKRPRJHQHLW\  DQG IDLOXUH ORDG  LQFUHDVHG EXW FRUWLFDO23 
WKLFNQHVV area (-2.9%) and pore volume (-1.6%) decreased. 24 
 25 
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Conclusions  1 
Teriparatide exerts differential effects on the central and the peripheral skeleton.  Central 2 
trabecular vBMD (L1-L3) LV LPSURYHG EXW WKHUH LV D FRQFRPLWDQW GHFUHDVH LQ SHULSKHUDO3 
FRUWLFDOY%0'DQGDQLQFUHDVHLQSRURVLW\Overall, we did not observe aFKDQJHLQWRWDOERG\4 
ERQHPLQHUDO:HDFNQRZOHGJHWKDWRXUFRQFOXVLRQVPD\EHVSHFXODWLYHDQGDUHFRQVWUDLQHG5 
E\WKHWHFKQLFDOOLPLWDWLRQVRIWKHLPDJLQJWHFKQLTXHVXVHGWKHODFNRIDFRQWUROJURXSDQGWKH6 
VPDOOVDPSOHVL]HVWXGLHG 7 
 8 
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 11 
Mini Abstract 12 
The central and peripheral skeleton were characterised using imaging techniques during 104-13 
weeks of teriparatide treatment.  Teriparatide exerts differential effects on the central and the 14 
peripheral skeleton. Overall, we did not observe a change in total body bone mineral. 2XU15 
FRQFOXVLRQVDUHFRQVWUDLQHGE\WKHVWXG\OLPLWDWLRQV 16 
 17 
  18 
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Introduction 1 
Teriparatide is the active fragment (1-34) of human parathyroid hormone.  It is one of only two 2 
anabolic agents licensed for the management of osteoporosis; the other being abaloparatide 3 
which received FDA approval in April 2017.  Teriparatide stimulates both bone formation and 4 
bone resorption and therefore has the potential to cause bone gain and bone loss [1-3]. 5 
The effects of teriparatide to increase lumbar spine areal bone mineral density (aBMD), as 6 
measured using dual-energy x-ray absorptiometry (DXA), are well established [4-8].  7 
However, calcium balance, assessed in the early development of teriparatide, did not show a 8 
positive balance [9].  Furthermore, a study that measured total body areal bone mineral content 9 
(aBMC) by DXA over a period of one year in patients on teriparatide following prior 10 
osteoporosis therapy also showed no significant change [10]. These studies suggest that there 11 
must be bone loss in some skeletal sites to balance the bone gain in the central skeleton. 12 
The mechanisms underlying teriparatide-induced changes in densitometric and geometric bone 13 
properties can be elucidated using techniques that allow interrogation of the separate bone 14 
compartments, i.e. quantitative computed tomography (QCT).  Mean changes in proximal 15 
femur total volumetric BMD (vBMD) of +1.2% and +0.5% and in lumbar spine total vBMD 16 
of +12.9% and +18.2% have been reported following 12 months of teriparatide treatment 17 
[4,11].  During the European Forsteo Observational Study (EUROFORS), 24 months of 18 
teriparatide resulted in increases in total vBMD of 4.0% at the proximal femur [12].  There is 19 
evidence that teriparatide exerts differential effects on the trabecular and cortical bone 20 
compartments.  Following 12 months of teriparatide treatment, Genant et al. [4] demonstrated 21 
an increase in proximal femur trabecular vBMD (4.0%) but a decrease in proximal femur 22 
cortical vBMD (-0.9%). Similar effects (proximal femur trabecular vBMD = +2.6% and 23 
proximal femur cortical vBMD = -2.6%) were observed during EUROFORS [12]. Borggrefe 24 
et al. [12] reported an increase in proximal femur trabecular vBMD (+5.2%) with 24 months 25 
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of teriparatide treatment, proximal femur cortical vBMD remained reduced (-2.0%), but 1 
cortical thickness increased in treatment-naïve patients.  An early decrease in proximal femur 2 
cortical BMD appears to be transient, caused by an increase in bone turnover and would not 3 
likely impact bone strength [12,13].  Finite element analysis of the spine revealed significant 4 
increases in both cortical (+16.2%) and trabecular (+21.4%) bone strength after 12 months of 5 
teriparatide treatment [13].   6 
 7 
High-resolution quantitative computed tomography (HR-QCT) can be used to provide some 8 
information about teriparatide-induced effects on the trabecular microstructure of vertebra T12.  9 
Graeff et al [11] reported increases in apparent trabecular number (app.Tb.N: +12.9%), 10 
apparent trabecular thickness (app.Tb.Th: +8.4%) and apparent bone volume:total volume 11 
(app.BV/TV: +23.3%) and a decrease in apparent trabecular separation (app.Tb.Sp: -10.5%) 12 
after treatment-naïve patients received 12 months of teriparatide.  However, Graeff et al. [11] 13 
concluded that it was not possible to accurately measure trabecular thickness or trabecular 14 
number due to the limited spatial resolution of the HR-QCT technique (DSSUR[LPDWHO\Pm) 15 
and report only changes in app.BV/TV (+54.7%) following 24 months of teriparatide treatment 16 
[14].  Finite element models revealed that vertebral bone strength in compression and in 17 
bending increased by +28.1% and +28.3% respectively at 24 months. 18 
 19 
The microstructural effects of teriparatide treatment on the peripheral skeleton (arms and legs) 20 
are not so well understood and are less frequently reported.  McDonald et al [15], Tsai et al 21 
[16] and Hansen et al [17] reported significant decreases in radius and tibia cortical vBMD 22 
(between -1.6% and -4.5%) and increases in cortical porosity (between +5.6 and +32.0%) 23 
following 12 and 18 months of teriparatide treatment, but these effects did not appear to impact 24 
on bone strength [15-17].  A consensus on the effects of teriparatide on the trabecular bone 25 
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compartment has yet to be reached, and the reporting of study findings is inconsistent [15-17]. 1 
 2 
Our study objective was to perform quantitative assessments of bone using imaging techniques 3 
to simultaneously characterise the central and peripheral skeleton over 104 weeks of treatment 4 
to better understand the mechanism of action of teriparatide.  To our knowledge this is the first 5 
study to simultaneously quantify the densitometric, microarchitectural and strength changes, 6 
induced during the licenced treatment duration for teriparatide, using DXA, QCT and HR-7 
pQCT. 8 
 9 
Materials and Methods 10 
Study Design 11 
We conducted a 104 week, single centre, single-arm, exploratory, open-label study of 12 
subcutaneous teriparatide at the licensed dose (Forsteo 20 mcg daily) to fully characterise its 13 
actions on the central and peripheral skeleton; the Mechanism Of Action of Teriparatide 14 
(MOAT) study. The study was registered with clinicalTrials.gov (http://clinicaltrials.gov/, 15 
number - NCT01293292) and with the European Union Drug Regulating Authorities Clinical 16 
Trials (EudraCT, number - 2010-021009-19). 17 
 18 
Study Population 19 
Postmenopausal women (n = 20, ages 65.4 ± 5.5 years) with osteoporosis, defined as an aBMD 20 
T score < -2.5 at the lumbar spine or proximal femur, were enrolled into the study.  All 21 
individuals were recruited in accordance with the Summary of Product Characteristics (SmPc).  22 
The recommended indications of the National Institute for Health and Care Excellence (NICE 23 
HTA 161, http://www.nice.org.uk/Guidance/TA161) were not applied during the recruitment 24 
process as these state that only patients who have failed on or are intolerant to bisphosphonates 25 
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should be prescribed teriparatide. Prior use of bisphosphonate would have affected the key 1 
study efficacy measures; hence, we only studied women who were bisphosphonate-naïve.  2 
Inclusion criteria specified that the women should be >5 years postmenopausal but aged <85 3 
years, ambulatory, with serum 25-hydroxyvitamin D >50 nmol/L (after oral cholecalciferol 4 
loading), and willing and able to give informed consent. Women with ongoing conditions or 5 
diseases known to cause abnormalities of calcium metabolism or skeletal health were not 6 
eligible to participate in the study. Individuals who were morbidly obese (body mass index 7 
(BMI)>35 kg/m2) or underweight (BMI<18 kg/m2) and those that had sustained a fracture in 8 
the past year were not enrolled. We identified women with postmenopausal osteoporosis from 9 
Sheffield metabolic bone clinics, general practitioner (GP) referrals for bone densitometry and 10 
via GP mail-outs. Former research participants who had consented to participate in future 11 
research projects were also approached. 12 
This study was approved by the North West 2 Research Ethics Committee ± Liverpool Central 13 
and the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, and all 14 
participants gave fully informed written consent before their participation.  All investigations 15 
were carried out in accordance with the ethical standards laid down in the 1964 Declaration of 16 
Helsinki and its later amendments, and in accordance with the International Conference on 17 
Harmonisation Good Clinical Practice (ICH GCP) guidelines.  18 
 19 
Study Intervention 20 
The study drug was teriparatide (Forsteo 20 mcg daily: Eli Lilly and Company, Basingstoke, 21 
UK).  Participants received 104 weeks of teriparatide treatment delivered by a daily self-22 
administered subcutaneous injection in the thigh or abdomen. The drug was supplied in pre-23 
filled pens which administered 20 mcg doses. All participants were trained in correct injection 24 
technique. 25 
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To ensure that all study volunteers were vitamin D replete before administration of the 1 
teriparatide, a 100,000 IU cholecalciferol (vitamin D3) load was given orally to each volunteer 2 
at the end of their screening visit (-9 weeks from baseline: week -9).  A blood sample to assess 3 
the serum 25-hydroxyvitamin D level was then taken at week -8. Sixteen of the twenty enrolled 4 
participants were vitamin D replete by week -8 (serum 25-hydroxyvitamin D = 84.0 ± 19.6 5 
nmol/L (mean ± SD)).   If the results of the blood test at week -8 revealed WKDWWKHYROXQWHHU¶V6 
serum 25-hydroxyvitamin D level <50 nmol/L, then a second loading dose was given at week 7 
-6.  Four of the twenty enrolled participants received a further 100,000 IU cholecalciferol load 8 
at week -6 as their serum 25-hydroxyvitamin D levels at week -8 was 29.3 ± 6.7 nmol/L.  A 9 
further blood sample to assess the serum 25-hydroxyvitamin D level was then taken at week -10 
5 in those four volunteers who had received a 100,000 IU cholecalciferol load at week -6 (week 11 
-5 serum 25-hydroxyvitamin D = 65.3 ± 6.1 nmol/L). Only volunteers with a serum 25-12 
hydroxyvitamin D level >50 nmol/L by week -5 were enrolled as study participants and 13 
received the study drug.  Further 100,000 IU cholecalciferol loads were administered to all 14 
study participants at six-monthly intervals throughout the study (weeks 26, 52 and 78) to ensure 15 
that they remained vitamin D replete. 16 
In keeping with usual clinical practice, all participants also received daily calcium (600mg) 17 
and vitamin D3 (400IU) supplements as Adcal D3 (Prostrakan: Galashiels, UK) throughout the 18 
study. 19 
 20 
Study drug compliance 21 
Study drug compliance was assessed at each study visit by measuring medication usage in the 22 
pre-filled pen syringe devices and comparing it to expected usage. If teriparatide usage was 23 
less than 75% of that expected for the number of days between visits, study participants were 24 
questioned further on their compliance and then a decision was made as to whether the 25 
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participant should continue on the study. Self-reported compliance was assessed at weeks 24, 1 
36 and 72 by telephone calls. 2 
Information regarding all adverse events (AEs) and serious adverse events (SAEs) collected 3 
from the participants, whether volunteered or discovered through questioning, was recorded 4 
and followed up in accordance with the study protocol guidelines. Concomitant medications 5 
were recorded for all participants during the study period. 6 
 7 
Anthropometric assessments 8 
Anthropometric measurements, height (to the nearest 0.1 cm) and weight (to the nearest 0.1 9 
kg), were measured using a wall-mounted stadiometer (Seca 242, Seca, Birmingham, UK) and 10 
an electronic column scale (Seca), respectively.  Body mass index was calculated to the nearest 11 
0.1 kg/m2. 12 
 13 
Dual-energy x-ray absorptiometry of the central and peripheral skeleton 14 
Areal BMD (in g/cm2) of the lumbar spine, right proximal femur and total body was measured 15 
at baseline, 26, 52 and 104 weeks by DXA using a Discovery A densitometer (Hologic Inc, 16 
Bedford MA).  Vertebral fracture assessments (VFA) by DXA were also performed at baseline 17 
and week 104 to identify prevalent and incident vertebral fractures.  All VFA images were 18 
visually assessed by a single operator (without measurement of vertebral dimensions) using the 19 
algorithm-based qualitative (ABQ) approach [18].  If a vertebral fracture was suspected, plain 20 
radiographs of the thoracic and lumbar spine in the anteroposterior and lateral projections were 21 
acquired. 22 
 23 
Quantitative computed tomography of the central skeleton 24 
Quantitative computed tomography (QCT) of vertebrae L1-L3 and the proximal femur was 25 
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performed at baseline, 26, 52, and 104 weeks using a 64-row LightSpeed volumetric computed 1 
tomography system (Lightspeed 64 VCT XT: GE Medical Systems). 2 
Images of L1-L3 were acquired in the axial plane with a helical full 1.0 s rotation time and a 3 
table height of 155 cm.  All scans were performed using the following scan settings: pitch = 4 
0.969, tube current = 140 mA, tube voltage = 80 kVp and slice thickness = 0.625 mm.  Scanning 5 
began 5mm above the superior endplate of L1 (inclusive of the T12-L1 joint space) and ended 6 
5mm below the inferior endplate of L3 (inclusive of the L3-L4 joint space).  Images were 7 
reconstructed at 0.625mm x 0.625mm using the standard algorithm and a field of view of 480 8 
mm.  Images were analysed using QCT Pro software (V5.0.3, Mindways Software Inc., Austin, 9 
TX, USA). Trabecular vBMD of vertebrae L1, L2, L3 and L1-L3 was determined by 10 
positioning an elliptical volume of interest (VOI) within the frontal trabecular region of each 11 
vertebral body to exclude the cortical and sub-cortical bone.   12 
Images of the proximal femur were acquired in the axial plane with a helical full 1.0 s rotation 13 
time and a table height of 155 cm.  All scans were performed using the following scan settings: 14 
pitch = 0.969, tube current = 200 mA, tube voltage = 120 kVp and slice thickness = 0.625 mm.  15 
Scanning began 3 cm above the head of the femur and ended 3 cm below the lesser trochanters.  16 
Images were reconstructed at 0.625mm x 0.625mm using the standard algorithm and a field of 17 
view of 480 mm.  Images were analysed using QCT Pro CTXA-Hip software (Mindways 18 
Software Inc., Austin, TX, USA) to yield values for total and integral vBMD and volumetric 19 
BMC (vBMC). 20 
A Model 3 CT density calibration phantom (Mindways, Mindways Software Inc.: Austin, TX, 21 
USA) was positioned under the participants during each L1-L3 and proximal femur scan. 22 
Information extracted from the calibration phantom allowed the conversion of measured 23 
Hounsfield units to units of bone mineral. 24 
 25 
11 
 
High-resolution peripheral quantitative computed tomography of the peripheral skeleton 1 
High-resolution peripheral quantitative computed tomography (HR-pQCT) examinations of 2 
the distal radius and distal tibia were performed at baseline, 12, 26, 52, 104 weeks using the 3 
XtremeCT (Scanco Medical AG, Zurich, Switzerland).  All examinations were performed on 4 
the non-dominant limb [20] except when a participant had sustained a prior fracture of the non-5 
dominant radius and/or tibia, in which case the contralateral limb was measured.  A maximum 6 
of one repeat scan at either or both anatomical sites was performed in the event of patient 7 
movement [21]. The quality of the HR-pQCT scan images was assessed by a single operator, 8 
using the visual grading system reported by Engelke et al. [22]. 9 
HR-pQCT image segmentation and analysis of densitometric, geometric and micro-structural 10 
bone properties were performed using the standard in-built software (version 6.0, Scanco 11 
Medical AG, Zurich, Switzerland).  Extended cortical bone analysis techniques were applied 12 
to the segmented scans following the approach described by Burghardt et al. [23]. Measures of 13 
bone strength, for the distal radius and tibia, were determined by finite element analysis using 14 
software developed by Scanco Medical AG (version 1.13; FE-solver included in the Image 15 
Processing Language) [24]. 16 
 17 
Statistical analyses 18 
Our sample size calculations were based on teriparatide-induced changes in lumbar spine 19 
aBMD in osteoporosis treatment-naïve patients.  A one standard deviation decrease in BMD 20 
has been associated with a 2-fold increase in the risk of spine fracture [25]. Thus, our clinically 21 
significant difference was a change from baseline of 1.0 standard deviation and we calculated 22 
that 16 patients would provide > 90% power, at the 5% significance level, to detect changes in 23 
lumbar spine aBMD due to teriparatide treatment.  Allowing for a 10% drop-out per year, a 24 
total of 20 women were recruited into the study. 25 
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We performed per-protocol analyses which only used data acquired from those participants 1 
who attended for all study visits, adhered to all study SURFHGXUHV DQGGHPRQVWUDWHG% 2 
compliance with study medication; referred to as completers.  A medication compliance 3 
threshold of 75% was chosen as it equated approximately to 5 injections of teriparatide per 4 
week.  Baseline demographics were reported as the mean ± standard deviation (SD).  Absolute 5 
and percentage change from baseline to all time-points for the physical measurement variables 6 
(mean ± SD or mean ± standard error of the mean (SEM)) were calculated.  Repeated measures 7 
ANOVA were used to assess changes in measurement variables after 52 and 104 weeks of 8 
teriparatide treatment.  Statistical analyses were performed using GraphPad Prism 6 for 9 
Windows (version 6.03. GraphPad Software, Inc.  La Jolla, CA 92037 USA). A level of p<0.05 10 
was considered to show statistical significance. 11 
 12 
Results 13 
Study population 14 
We recruited twenty postmenopausal women with osteoporosis into the MOAT study. 15 
Summary information on the number of individuals screened, enrolled, withdrawn and 16 
progressing to each further study phase is shown as a CONSORT diagram in Figure 1.  17 
Examination of the baseline self-reported fracture history revealed that 11 participants had 18 
sustained a total of 16 prior non-vertebral fractures, comprising fractures of the foot (n = 5), 19 
wrist (n = 4), ankle (n = 2), pelvis (n = 4), hand (n = 1), ribs (n = 1) and clavicle (n = 1).  There 20 
was no evidence of prior vertebral fractures as assessed by VFA. 21 
Sixteen of the twenty women completed the 2-year study as per protocol. Nineteen participants 22 
FRPSOHWHGZHHNVEXWZHHNVRIWHULSDUDWLGHWUHDWPHQWUDQJH= 52 to 87 weeks), and 23 
one participant completed 35 weeks of teriparatide treatment.  Baseline demographic details 24 
were similar for those participants enrolled on and those completing the MOAT study (Table 25 
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1). 1 
Changes in aBMD and aBMC within the lumbar spine and proximal femur (central skeleton) 2 
Following 52 weeks of teriparatide treatment, lumbar spine aBMC (+11.2 ± 4.5%; p<0.0001) 3 
and aBMD (+8.1 ± 3.2%; p<0.0001) increased.  Further increases in lumbar spine aBMC (+5.2 4 
± 6.0%; p=0.004 week 52 versus week 104) and aBMD (+3.7 ± 4.2%; p=0.004 week 52 versus 5 
week 104) were observed between weeks 52 and 104.  Increases in lumbar spine aBMC of 6 
+16.4 ± 7.6% (p<0.0001 versus baseline) and aBMD of +11.8 ± 5.8% (p<0.0001 versus 7 
baseline) occurred by 104 weeks. 8 
Following 104 weeks of teriparatide treatment, no significant changes in total proximal femur 9 
aBMC, total proximal femur aBMD, femoral neck aBMC or femoral neck aBMD were evident. 10 
 11 
Changes in aBMD and aBMC within the whole body (central and peripheral skeleton) 12 
Changes in total body and sub-regional aBMC and aBMD following 104 weeks of teriparatide 13 
treatment are presented in Table 2.  Overall, there was no significant change in total body or 14 
sub-total body aBMD and aBMC.  When examining the total body sub-regions at week 104 15 
however, increases in aBMC and aBMD occurred in the lumbar spine and pelvis.  Areal BMD 16 
increased within the thoracic spine.  In contrast, aBMC and aBMD decreased in the legs. Areal 17 
BMC decreased in the skull and arms. 18 
 19 
Changes in QCT measures of L1-L3 and the proximal femur (central skeleton) 20 
Changes in QCT measures of L1-L3 and the proximal femur are presented in Table 3.  By week 21 
52, L1-L3 vBMD increased.  No further increases in L1-L3 vBMD occurred by week 104.  22 
Proximal femur total vBMD remained unchanged.  By week 52, increases in trabecular vBMD 23 
of the proximal femur and concomitant decreases in proximal femur cortical vBMD were 24 
evident.  These initial changes did not appear to affect proximal femur strength, as there was 25 
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no significant change in buckling ratio.   By week 104, no significant changes in proximal 1 
femur total, trabecular and cortical vBMD or vBMC and cross-sectional area were apparent.   2 
 3 
Changes in HR-pQCT measures of the radius and tibia (peripheral skeleton) 4 
Effects of teriparatide treatment were also observed in the peripheral skeleton.  Changes in HR-5 
pQCT measures at the radius and tibia are presented in Table 4.  By week 52, radius cortical 6 
TMD, tibia cortical TMD and tibia endosteal perimeter decreased. An increase in radius 7 
cortical porosity was also observed.  By week 104, differential effects due to teriparatide 8 
treatment were observed between (i) the radius and the tibia and (ii) the trabecular and cortical 9 
bone compartments.  Radius and tibia cortical vBMD, cortical TMD and total vBMD decreased 10 
by week 104.  There was a concomitant increase in cortical porosity at both anatomical sites.  11 
At the tibia, teriparatide-induced effects included decreases in cortical thickness, cortical area 12 
and cortical pore diameter and increases in the endocortical perimeter, periosteal perimeter, 13 
trabecular area, trabecular inhomogeneity and failure load.  All other radius and tibia 14 
parameters remained unchanged. 15 
 16 
Evidence for Redistribution of Bone Mineral 17 
We observed a loss of 35.01 ± 8.86 g (mean ± SEM) (95% CI = -53.89 to -16.14 g, p=0.001) 18 
of bone mineral from the peripheral skeleton and a gain of 28.23 ± 5.32 g (mean ± SEM) (95% 19 
CI = +16.89 to +39.57 g, p<0.0001) of bone mineral within the central skeleton (Table 2).  This 20 
is equivalent to a -4.09 ± 1.08 % (mean ± SEM) (95% CI = -6.39 to -1.79 %, p=0.002) loss of 21 
bone mineral from the peripheral skeleton and an 8.52 ± 1.57 % (mean ± SEM) (95% CI = 22 
+5.16 to +11.87 %, p<0.0001) gain in bone mineral within the central skeleton.  From these 23 
results we can infer that there is a redistribution of bone mineral from the peripheral to the 24 
central skeleton. Thus, as a minimum, there would be a gain in 17g of mineral in the central 25 
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skeleton and a loss of 16g from the peripheral skeleton as these are the 95% confidence limits. 1 
These are sizeable fluxes in bone mineral and therefore of clinical significance. 2 
 3 
Adverse Events 4 
Adverse events consisted of (i) gastrointestinal disorder; nausea, vomiting and reflux (n = 7), 5 
(ii) nervous system disorder; headache and dizziness (n = 3), (iii) injection site reaction; 6 
inflammation (n = 2), (iv) cardiac disorder; palpitations (n = 2), and (v) musculoskeletal 7 
disorder; (n = 2). There was one incident fracture of the ankle.  No incident vertebral fractures 8 
occurred during the 2 year study. 9 
 10 
Discussion 11 
The MOAT Study is the first study to simultaneously quantify densitometric, 12 
microarchitectural and strength changes due to 104 weeks of teriparatide treatment using DXA, 13 
QCT and HR-pQCT. It demonstrates that teriparatide treatment exerts differential effects on 14 
the central and peripheral skeleton.  Our in-depth characterisation of these skeletal changes 15 
contributes to a better understanding of the mechanism of action of teriparatide within the 16 
trabecular and cortical bone compartments. 17 
 18 
In the MOAT Study, no significant changes in total body aBMC or aBMD occurred as a result 19 
of 104 weeks of teriparatide therapy for postmenopausal osteoporosis in bisphosphonate-naïve 20 
patients.  The observed increase in bone mineral in the spine and pelvis appears to be countered 21 
by a decrease in bone mineral in the arms, legs and skull.  It could be inferred that there is a 22 
redistribution of bone mineral from the peripheral to the central skeleton.  Loss of bone mineral 23 
from the skull during teriparatide treatment has been revealed by isotope bone scanning [26]; 24 
similar effects are observed in patients with primary and secondary hyperparathyroidism 25 
16 
 
µSHSSHUSRW VNXOO¶  :KHQ WHULSDUDWLGH ZDV DGPLQLVWered to treatment-naïve patients at its 1 
licenced dose (20 Pg daily), no significant changes in sub-total body BMD were evident [27-2 
30].  Neer et al however, demonstrated a +3.1 ± 4.3% increase in total body aBMD when using 3 
only GE/Lunar DXA devices [28].  One study examined changes in total body aBMC with the 4 
head, but again, no significant changes were observed [31]. 5 
 6 
Our study demonstrates that teriparatide treatment exerts differential effects on the trabecular 7 
and cortical bone compartments within the central skeleton. 8 
:LWKLQWKHFHQWUDOVNHOHWRQVLJQLILFDQWLQFUHDVHVLQVSLQHD%0'D%0&DQGWUDEHFXODUY%0'9 
ZHUHHYLGHQWIROORZLQJDQGZHHNVRIWHULSDUDWLGHWUHDWPHQW7KLVLVLQNHHSLQJZLWKWKH10 
ILQGLQJVRI*HQDQWHWDO>@.OHHUNRSHUHWDO>@0L\DXFKLHWDO>@DQGWKH(852)25611 
VWXG\ >@ :HREVHUYHG LQFUHDVHV LQ VSLQH %0'DQG D%0& DV HDUO\ DV ZHHNV DIWHU12 
WUHDWPHQWFRPPHQFHPHQW 13 
5HSRUWHG ILQGLQJV IURP KLVWRPRUSKRPHWULF DQG ERQH WXUQRYHU PDUNHU VWXGLHV HQDEOH XV WR14 
EHWWHUXQGHUVWDQG WKHPHFKDQLVPVEHKLQG WKHVH ODUJH DQGHDUO\ FKDQJHV LQ WUDEHFXODUERQH15 
+LVWRPRUSKRPHWULFVWXGLHVKDYHVKRZQWKDW WKHHIIHFWVRI WHULSDUDWLGHRQERQHDW WKH WLVVXH16 
OHYHO EHJLQ ZLWK DQ LQFUHDVH LQ DFWLYDWLRQ IUHTXHQF\ >@  :LWKLQ WKH ILUVW IHZ ZHHNV RI17 
WUHDWPHQWWKHUHLVDSUHIHUHQWLDOVWLPXODWLRQRIWUDEHFXODUERQHIRUPDWLRQRYHUERQHUHVRUSWLRQ18 
$WWKHFHOOXODUOHYHOWHULSDUDWLGHH[HUWVLWVHIIHFWVWKURXJKWZRPDLQPHFKDQLVPVLQKLELWLRQRI19 
RVWHREODVWDSRSWRVLVDQGVWLPXODWLRQRIRVWHREODVWSUROLIHUDWLRQ>@ 2YHUDOO WKHUHLVDQ20 
LQFUHDVHLQPRGHOOLQJDWSUHYLRXVO\TXLHVFHQWERQHVXUIDFHVDQGDQRYHUILOOLQJRIUHPRGHOOLQJ21 
VLWHVOHDGLQJWRDQHYHQWXDOLQFUHDVHLQERQHPDVV>@DQGDQLPSURYHPHQWLQWUDEHFXODU22 
PLFURDUFKLWHFWXUH 23 
By week 52, increases in trabecular vBMD of the proximal femur and concomitant decreases 24 
in proximal femur cortical vBMD were evident. However, there was no overall change in 25 
17 
 
proximal femur total vBMD. These early changes in aBMC, vBMC and vBMD have been 1 
reported previously and do not appear to impact femoral bone strength >@.  During 2 
the MOAT Study, no significant changes in total proximal femur aBMC and aBMD or 3 
proximal femur vBMC and vBMD were apparent following 104 weeks of teriparatide 4 
treatment.  Our 52-week findings are in keeping with those reported by Genant et al. [4], 5 
Obermayer-Pietsch et al. [7] and Borgreffe et al. [12]+RZHYHURXUZHHNILQGLQJVGLIIHU6 
IURPWKRVHRIWKH(852)256VWXG\>@2EHUPD\HU3LHWVFKHWDO>@DQG%RUJUHIIHHWDO7 
>@ UHSRUWHG LQFUHDVHG WRWDO SUR[LPDO IHPXU D%0' DQG Y%0' LQ WKH (852)256 6WXG\8 
IROORZLQJPRQWKVRIWHULSDUDWLGHWUHDWPHQW>@$OWKRXJKWKHUHZDVDQLQFUHDVHLQSUR[LPDO9 
IHPXUWUDEHFXODUY%0'FRUWLFDOY%0'DQGEXFNOLQJUDWLRZDVVWLOOUHGXFHG>@ 10 
7KHSUR[LPDOIHPXULVDVNHOHWDOVLWHFRPSULVLQJERWKFRUWLFDODQGWUDEHFXODUERQHLQFRQWUDVW11 
WRWKHYHUWHEUDHZKLFKFRQVLVWSUHGRPLQDQWO\RIWUDEHFXODUERQH7KHPHFKDQLVPRIDFWLRQRI12 
WHULSDUDWLGHZLWKLQWKHIHPXUFDQEHH[SODLQHGWKURXJKLWVHIIHFWVRQERWKERQHFRPSDUWPHQWV13 
7KHUHLVHYLGHQFHWKDWWHULSDUDWLGHVLPXOWDQHRXVO\LQGXFHVERWKSHULRVWHDODSSRVLWLRQRIQHZ14 
ERQH DQG HQGRVWHDO UHVRUSWLRQ RI ROG ERQH ZLWKLQ WKH FRUWLFDO ERQH FRPSDUWPHQW >@15 
,QLWLDOO\ ROGHU KLJKO\ PLQHUDOLVHG ERQH LV UHPRYHG WKURXJK µLQWUDFRUWLFDO WXQQHOOLQJ¶  7KH16 
SRUHVWKDWUHVXOWDUHWKHQILOOHGZLWKQHZERQHWKHUHIRUHDQ\LQLWLDOGHFUHDVHLQ%0'LVWUDQVLHQW17 
>@ %\ZHHN WKHUH DSSHDUV WREH D UHVROXWLRQRI WKHVH HIIHFWV WKURXJK WKHSURFHVVRI18 
WUDEHFXODUERQHIRUPDWLRQDQGPLQHUDOLVDWLRQRIWKHRVWHRLG1RGHOHWHULRXVHIIHFWVRQIHPRUDO19 
ERQHVWUHQJWKKDYHEHHQUHSRUWHGGHVSLWHWKLVLQLWLDOFDWDEROLFDFWLRQRIWHULSDUDWLGHRQFRUWLFDO20 
ERQH>@ 2XUVWXG\ILQGLQJVHPSKDVLVH WKH LPSRUWDQFHRIFRPSOHWLQJD IXOOZHHN21 
FRXUVHRIWUHDWPHQWRQO\ WKHQFDQWKHIXOODQDEROLFHIIHFWRIWHULSDUDWLGHEHREVHUYHGDW WKH22 
IHPXU>@ 23 
Our study also demonstrates that teriparatide treatment exerts differential effects (i) within the 24 
central (spine, trunk and proximal femur) and peripheral (arms and legs) skeleton, (ii) within 25 
18 
 
the trabecular and cortical bone compartments of the peripheral skeleton and (iii) on the radius 1 
and tibia. 2 
:LWKLQWKHDUPVDQGWKHOHJVZHREVHUYHGDGHFUHDVHLQD%0&DQGD%0'7KHUHZDVDOVRD3 
VLJQLILFDQWGHFUHDVHLQD%0&DQGD%0'RIWKHVNXOO 4 
$WERWKWKHUDGLXVDQGWKHWLELDZHREVHUYHGDGHFUHDVHLQWRWDOY%0'FRUWLFDOY%0'DQG5 
FRUWLFDO 70' ZLWK D FRQFRPLWDQW LQFUHDVH LQ FRUWLFDO SRURVLW\ IROORZLQJ  ZHHNV RI6 
WUHDWPHQW$OVRDWWKHWLELDWKHUHZDVDGHFUHDVHLQFRUWLFDODUHDWKLFNQHVVDQGSRUHGLDPHWHU7 
ZLWKDFRQFRPLWDQWLQFUHDVHLQWKHHQGRVWHDODQGSHULRVWHDOSHULPHWHUV$WWKHUDGLXVWKHUHZDV8 
QRDSSDUHQW FKDQJH LQ WKH WUDEHFXODUERQHFRPSDUWPHQWKRZHYHU DW WKH WLELD WKHUHZDV DQ9 
LQFUHDVH LQ WUDEHFXODU DUHD DQG LQKRPRJHQHLW\  7KHVH FKDQJHV LQ ERWK WKH FRUWLFDO DQG10 
WUDEHFXODUERQHFRPSDUWPHQWVDSSHDU WRKDYHPLQLPDO LPSDFWRQERQHVWUHQJWKDOWKRXJKD11 
VOLJKW GHFUHDVH LQ WLELD IDLOXUH ORDG ZDV REVHUYHG  2XU ILQGLQJV DUH LQ NHHSLQJ ZLWK WKRVH12 
UHSRUWHGE\0F'RQDOGHWDO>@7VDLHWDO>@DQG+DQVHQHWDO>@ 13 
:HSURSRVH WKDW WKHSUHGRPLQDQWPHFKDQLVPRIDFWLRQRI WHULSDUDWLGHZLWKLQ WKHSHULSKHUDO14 
VNHOHWRQ LV WKURXJK LWV HIIHFW RQ FRUWLFDO ERQH$V GHVFULEHG DERYH WKH FDWDEROLF HIIHFWV RI15 
WHULSDUDWLGH DUH PHGLDWHG WKURXJK WKH UHPRYDO RI ROG KLJKO\ PLQHUDOLVHG ERQH DQG WKH16 
DSSRVLWLRQ RI QHZ RVWHRLG $Q\ DQDEROLF HIIHFWV RQ WKH WUDEHFXODU ERQH LQ WKH SHULSKHUDO17 
VNHOHWRQDSSHDUWREHPLQLPDO'HVSLWHWKHREVHUYHGLQFUHDVHLQFRUWLFDOSRURVLW\DWWKHUDGLXV18 
DQGWKHWLELDSHULSKHUDOERQHVWUHQJWKPHDVXUHVUHPDLQHGDOPRVWXQFKDQJHG7KLVLVLQNHHSLQJ19 
ZLWKSUHYLRXVO\UHSRUWHGILQGLQJVIROORZLQJDQGPRQWKVRIWHULSDUDWLGHWUHDWPHQW>@20 
7KHGLIIHUHQWLDOHIIHFWVREVHUYHGDWWKHWLELDDQGUDGLXVPD\UHVXOWIURPWKHGLIIHUHQWORDGLQJ21 
FRQGLWLRQV XQGHU ZKLFK WKH WZR ORQJ ERQHV DUH SODFHG GXULQJ GDLO\ DFWLYLWLHV LH ZHLJKW22 
EHDULQJDQGQRQZHLJKWEHDULQJ 23 
2XUVWXG\GRHVKDYHOLPLWDWLRQV7KLVZDVDQRSHQODEHOVWXG\RISRVWPHQRSDXVDOZRPHQ24 
ZLWKRVWHRSRURVLV:HGLGQRWLQFOXGHDFRQWUROJURXS:HDVVXPHGWKDWWKHRSHQODEHOGHVLJQ25 
19 
 
ZRXOGQRWLQIOXHQFHWKHVWXG\RXWFRPHVDQGWKHLQFOXVLRQRIDFRQWUROJURXSRISRVWPHQRSDXVDO1 
ZRPHQZLWKRVWHRSRURVLVZDVGHHPHGWREHXQHWKLFDO$V all the enrolled participants received 2 
loading doses of 100,000 IU cholecalciferol to ensure that they were vitamin D replete before 3 
receiving and during teriparatide treatment, they were not representative of a typical patient 4 
group.  All participants also received daily calcium and vitamin D3 supplements throughout 5 
the study.  Although this is in keeping with usual clinical practice, the dose of the supplements 6 
prescribed to participants does differ between studies.  For example, women participating in 7 
the MOAT Study received lower daily doses of calcium (600mg versus 1000mg), and vitamin 8 
D3 (400 IU versus 400 to 1200 IU) compared to the women studied by Neer et al. [28].  With 9 
these caveats in mind, we acknowledge that the changes observed within the central and 10 
peripheral skeleton during the MOAT Study cannot be unequivocally attributed to teriparatide 11 
treatment alone. 12 
7KHWHFKQLFDOOLPLWDWLRQVRIWKHLPDJLQJWHFKQLTXHVXVHGPXVWDOVREHDFNQRZOHGJHG)LUVWO\13 
DXA cannot provide information about separate bone compartments or bone microstructure. 14 
Moreover during the MOAT study, we observed that when added together the total body sub-15 
regional changes in aBMC did not equate to the overall change in total body aBMC, thus further 16 
demonstrating the limitations of DXA.  Secondly, 4&7FDQQRWEHXVHGWRGLUHFWO\PHDVXUHWKH17 
HIIHFWV RI WHULSDUDWLGH WUHDWPHQW RQ YHUWHEUDO WUDEHFXODU PLFURDUFKLWHFWXUH DV WKH VSDWLDO18 
UHVROXWLRQRIWKHWHFKQLTXHLVFKDUDFWHULVHGE\YR[HOVL]HVODUJHUWKDQWKHW\SLFDOGLDPHWHURI19 
WKH LQGLYLGXDO WUDEHFXODH :HKDYH WKHUHIRUHDVVXPHG WKDW WKH LQFUHDVH LQYHUWHEUDOY%0'20 
UHIOHFWVDQLPSURYHPHQWLQYHUWHEUDO WUDEHFXODUPLFURDUFKLWHFWXUH 7KHXVHRI+54&7ZDV21 
FRQVLGHUHGKowever Graeff et al. [11] concluded that it was not possible to accurately measure 22 
trabecular thickness or trabecular number due to the limited spatial resolution of the HR-QCT 23 
technique (DSSUR[LPDWHO\Pm).  )LQDOO\FXUUHQWLPDJLQJWHFKQRORJLHVDOVROLPLWRXUDELOLW\24 
WRLQYHVWLJDWHZKHWKHUERQHPLQHUDOLVUHGLVWULEXWHGZLWKLQWKHVDPHERQH+5S4&7FDQEH25 
20 
 
XVHGWRVWXG\WKHFRUWLFDODQGWUDEHFXODUERQHFRPSDUWPHQWV LQGHSHQGHQWO\EXW LWFDQQRWEH1 
XVHGWRGHWHUPLQHZKHWKHUERQHPLQHUDOLVUHGLVWULEXWHGIURPXOWUDGLVWDOWRPRUHSUR[LPDOVLWHV2 
ZLWKLQWKHUDGLXVDQGWKHWLELD 3 
,Q VXPPDU\ WKH PHFKDQLVP RI DFWLRQ RI WHULSDUDWLGH WR LQFUHDVH %0' ZLWKLQ WKH FHQWUDO4 
VNHOHWRQDSSHDUVWREHSUHGRPLQDQWO\GXHWRDQLPSURYHPHQWLQWUDEHFXODUPLFURDUFKLWHFWXUH5 
,Q FRQWUDVW ZLWKLQ WKH SHULSKHUDO VNHOHWRQ FRUWLFDO %0' GHFUHDVHV SULPDULO\ WKURXJK D6 
UHGXFWLRQLQFRUWLFDO70'DQGDQLQFUHDVHLQFRUWLFDOSRURVLW\ 7 
7RFRQFOXGHWHULSDUDWLGHH[HUWVGLIIHUHQWLDOHIIHFWVRQWKHFHQWUDODQGWKHSHULSKHUDOVNHOHWRQ8 
7UDEHFXODUPLFURDUFKLWHFWXUH LV LPSURYHGEXW WKHUH LV DFRQFRPLWDQWGHFUHDVH LQSHULSKHUDO9 
FRUWLFDOY%0'DQGDQLQFUHDVHLQSRURVLW\Overall, we did not observe a change in total body 10 
bone mineral.  :H DFNQRZOHGJH WKDW RXU FRQFOXVLRQV DUH FRQVWUDLQHG E\ WKH WHFKQLFDO11 
OLPLWDWLRQVRI';$4&7DQG+5S4&7WKHODFNRIDFRQWUROJURXSDQGWKHVPDOOVDPSOHVL]H12 
VWXGLHG2XUK\SRWKHVLVWKDWWHULSDUDWLGHUHVXOWVLQWKHUHGLVWULEXWLRQRIERQHPLQHUDOIURPWKH13 
SHULSKHUDOWRWKHFHQWUDOVNHOHWRQLVVSHFXODWLYH 14 
7KH 02$7 6WXG\ FRQWULEXWHV WR a better understanding of the mechanism of action of 15 
teriparatide KRZHYHU RXU VWXG\ ILQGLQJV VKRXOG EH LQWHUSUHWHG ZLWK FDXWLRQ ZKHQ WUHDWLQJ16 
SDWLHQWVZLWKLQWKHFOLQLFDOVHWWLQJ 17 
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Table 1. Baseline demographics for all participants (i) enrolled on the MOAT study and (ii) 1 
completing the MOAT study as per protocol (completers).  All data are mean ± SD except 2 
number of participants and vertebral fracture at baseline which are shown as n. 3 
 4 
Demographic All enrolled participants All completers 
N 20 16 
Age (years) 65.4 ± 5.5 64.6 ± 4.5 
Height (cm) 160.9 ± 4.4 162.3 ± 3.1 
Weight (kg) 64.3 ± 8.1 64.1 ± 8.8 
Body Mass Index (kg/m2) 24.9 ± 3.8 24.4 ± 3.8 
Lumbar spine aBMD T-score 
-2.8 ± 0.3 -2.8 ± 0.2 
Total proximal femur aBMD T-score 
-2.2 ± 0.5 -1.5 ± 0.7 
Femoral neck aBMD T-score 
-1.5 ± 0.6 -2.1 ± 0.5 
Vertebral fracture at baseline 0 0 
Abbreviations: aBMD = areal bone mineral density5 
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Table 2. Absolute and percent changes in total body and sub-regional aBMC and aBMD in response to 104 weeks of teriparatide treatment.  Data are 
shown as mean ± SEM and 95% CI.  p values are given to 1 significant figure. 
Region 
Baseline absolute aBMC 
(g) 
Absolute change in 
aBMC (g) 
95% CI for absolute 
change in aBMC (g) p 
% change in aBMC 
(%) 
95% CI for % change 
in aBMC (%) p 
Total body 1669.00 ± 33.68 -20.07 ± 15.88 -53.92 to +13.79 0.2 -1.17 ± 0.94 -3.17 to +0.84 0.2 
Sub-total body 1258.00 ± 27.69 +0.32 ± 11.62 -24.45 to +25.10 0.9 -0.04 ± 0.90 -1.96 to +1.88 0.9 
Skull 411.40 ± 21.10 -20.39 ± 6.69 -34.64 to -6.134 0.008 -4.96 ± 1.87 -8.94 to -0.98 0.02 
Arms 118.80 ± 3.41 -5.88 ± 1.22 -8.49 to -3.27 0.0002 -5.12 ± 1.08 -7.43 to -2.81 0.0003 
Thoracic spine 84.63 ± 2.91 +5.03 ± 2.86 -1.07 to +11.13 0.1 +7.20 ± 3.97 -1.26 to +15.67 0.09 
Lumbar spine 34.98 ± 1.58 +7.66 ± 1.40 +4.69 to +10.64 <0.0001 +23.49 ± 4.34 +14.24 to +32.74 <0.0001 
Ribs 57.50 ± 2.36 +1.34 ± 1.89 -2.69 to +5.36 0.5 +3.07 ± 3.42 -4.24 to +10.37 0.4 
Pelvis 157.80 ± 5.17 +14.19 ± 3.23 +7.32 to +21.07 0.0005 +9.29 ± 2.09 +4.83 to +13.75 0.0005 
Legs 313.80 ± 40.04 -8.75 ± 3.30 -15.78 to -1.71 0.02 -2.94 ± 1.07 -5.21 to -0.67 0.01 
Central skeleton 334.90 ± 6.33 +28.23 ± 5.33 +16.89 to +39.57 <0.0001 +8.52 ± 1.57 +5.16 to +11.87 <0.0001 
Peripheral skeleton 844.00 ± 23.28 -35.01 ± 8.86 -53.89 to -16.14 0.001 -4.09 ± 1.08 -6.39 to -1.79 0.002 
Region 
Baseline absolute aBMD 
(g/cm2) 
Absolute change in 
aBMD (g/cm2) 
95% CI for absolute 
change in aBMD (g/cm2) p 
% change in aBMD 
(%) 
95% CI for % change 
in aBMD (%) p 
Total body 0.921 ± 0.013 -0.005 ± 0.006 -0.017 to +0.007 0.4 -0.52 ± 0.63 -1.85 to +0.82 0.4 
Sub-total body 0.786 ± 0.009 +0.003 ± 0.004 -0.006 to +0.013 0.4 +0.41 ± 0.55 -0.76 to +1.58 0.5 
Skull 1.932 ± 0.077 -0.053 ± 0.026 -0.110 to +0.003 0.06 -2.78 ± 1.48 -5.95 to +0.38 0.08 
Arms 0.606 ± 0.009 +0.006 ± 0.004 -0.014 to +0.001 0.09 -1.12 ± 0.60 -2.40 to +0.16 0.08 
Thoracic spine 0.677 ± 0.017 +0.049 ± 0.013 +0.022 to +0.076 0.002 +7.46 ± 1.95 +3.31 to +11.61 0.002 
Lumbar spine 0.775 ± 0.015 +0.090 ± 0.015 +0.058 to +0.122 <0.0001 +11.94 ± 2.11 +7.45 to +16.42 <0.0001 
Ribs 0.513 ± 0.038 +0.008 ± 0.007 -0.007 to +0.024 0.3 +1.84 ± 1.41 -1.17 to +4.84 0.2 
Pelvis 0.986 ± 0.022 +0.042 ± 0.009 +0.023 to +0.061 0.0003 +4.27 ± 0.87 +2.41 to +6.12 0.0002 
Legs 0.960 ± 0.016 -0.011 ± 0.004 -0.020 to -0.002 0.02 -2.47 ± 0.71 -3.98 to -0.95 0.004 
Central skeleton 2.952 ± 0.025 +0.189 ± 0.027 +0.132 to +0.247 <0.0001 +6.43 ± 0.91 +4.49 to +8.38 <0.0001 
Peripheral skeleton 3.497 ± 0.076 -0.071 ± 0.027 -0.129 to -0.013 0.02 -2.19 ± 0.83 -3.95 to -0.42 0.02 
Abbreviations: aBMD = areal bone mineral density, aBMC = areal bone mineral content, SEM = standard error of the mean, 95% CI = 95% confidence intervals 
Definitions: Central skeleton = spine, ribs and pelvis.  Peripheral skeleton = skull, arms and legs 
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Table 3. Absolute baseline values and percent changes in bone parameters as assessed using QCT of L1-L3 and the 
proximal femur in response to 52 and 104 weeks of teriparatide treatment.  All data are shown as mean ± SD and p 
values are given to 1 significant figure. 
 
Site Bone parameter 
Absolute 
baseline 
Week 52 Week 104 
Change (%) p Change (%) p 
Spine L1-L3 Trabecular vBMD (mg/cm3) 87.5 ± 18.6 +25.5 ± 12.3 <0.0001 +28.5 ± 19.4 <0.0001 
Proximal 
femur 
Total vBMD (mg/cm3) 253.8 ± 39.6 +1.5 ± 14.2 0.7 +2.5 ± 22.0 0.7 
Trabecular vBMD (mg/cm3) 118.0 ± 15.1 +5.7 ± 5.8 0.008 +3.4 ± 21.7 0.6 
Cortical vBMD (mg/cm3) 1,013.4 ± 92.1 -4.9 ± 5.6 0.01 +0.6 ± 13.5 0.9 
Total vBMC (mg) 24,540 ± 4658 +2.4 ± 27.4 0.8 +1.3 ± 34.8 0.9 
Trabecular vBMC (mg) 9,618 ± 1307 +3.9 ± 7.3 0.08 -2.0 ± 20.7 0.7 
Cortical vBMC (mg) 14,922 ± 3751 +3.6 ± 43.1 0.8 +6.1 ± 49.6 0.7 
Total CSA (cm2) 8.7 ± 1.6 -2.6 ± 10.7 0.4 -2.3 ± 11.4 0.5 
Trabecular CSA (cm2) 6.9 ± 1.4 -3.6 ± 10.7 0.3 -3.6 ± 15.0 0.4 
Cortical CSA (cm2) 1.8 ± 0.3 +2.2 ± 16.6 0.7 +3.1 ± 12.8 0.4 
Buckling ratio (1) 9.2 ± 1.4 -3.4 ± 10.2 0.3 -4.0 ± 19.8 0.5 
 
Abbreviations: vBMD = Volumetric bone mineral density, vBMC = volumetric bone mineral content, CSA = cross-sectional area. 
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Table 4. Absolute baseline values and percent changes in bone parameters as assessed using HR-
pQCT at the distal radius and distal tibia in response to 52 and 104 weeks of teriparatide treatment.  
All data are shown as mean ± SD and p values are given to 1 significant figure. 
 
Bone parameter Absolute baseline 
Week 52 Week 104 
Change 
(%) 
p Change (%) p 
RADIUS      
Total vBMD (mgHA/cm3) 222.9 ± 48.5 -0.1 ± 4.9 0.9 -2.8 ± 6.7 0.03 
Stiffness (kN/mm) 53.3 ± 7.4 +0.1 ± 9.1 0.9 +0.7 ± 8.1 0.5 
Failure load (kN) 2.76 ± 0.40 +0.3 ± 8.4 0.9 +0.6 ± 7.0 0.5 
Trabecular area (mm2) 255.72 ± 45.34 -0.2 ± 0.9 0.5 -0.4 ± 1.6 0.9 
Trabecular vBMD (mgHA/cm3) 120.3 ± 36.0 +0.7 ± 3.1 0.5 -1.4 ± 6.3 0.4 
Trabecular number (mm-1) 1.78 ± 0.40 -2.0 ± 7.8 0.4 -3.5 ± 7.6 0.2 
Trabecular thickness (mm) 0.056 ± 0.008 +3.2 ± 8.2 0.2 +2.7 ± 8.0 0.4 
Trabecular separation (mm) 0.536 ± 0.142 +2.4 ± 8.5 0.3 +4.2 ± 8.3 0.1 
Trabecular inhomogeneity (mm-1) 0.29 ± 0.17 +2.2 ± 5.4 0.2 +4.6 ± 7.1 0.2 
Trabecular BV/TV (%) 10.01 ± 3.00 +0.8 ± 3.3 0.4 -1.2 ± 6.4 0.5 
Cortical area (mm2) 35.40 ± 7.32 -0.4 ± 10.7 0.9 -4.5 ± 12.9 0.05 
Cortical vBMD (mgHA/cm3) 772.0 ± 61.2 -1.5 ± 4.5 0.3 -3.3 ± 5.8 0.004 
Cortical thickness (mm) 0.48 ± 0.12 -0.4 ± 10.9 0.9 -4.7 ± 12.3 0.08 
Periosteal perimeter (mm) 79.59 ± 8.20 +2.0 ± 5.5 0.2 -0.3 ± 4.2 0.7 
Endocortical perimeter (mm) 74.11 ± 8.17 +0.4 ± 6.4 0.8 -0.4 ± 4.3 0.9 
Cortical porosity (%) 2.89 ± 0.97 +11.9 ± 17.9 0.04 +21.2 ± 20.7 <0.0001 
Cortical TMD (mgHA/cm3) 976.6 ± 40.0 -2.5 ± 3.1 0.02 -3.2 ± 4.2 0.005 
Cortical pore diameter (mm) 0.172 ± 0.028 -2.2 ± 6.9 0.3 -1.3 ± 6.5 0.7 
TIBIA      
Total vBMD (mgHA/cm3) 232.2 ± 50.9 +0.2 ± 3.9 0.9 -2.5 ± 5.5 0.008 
Stiffness (kN/mm) 160.1 ± 22.6 +1.7 ± 3.6 0.08 -5.6 ± 23.1 0.2 
Failure load (kN) 8.11 ± 1.09 +1.6 ± 3.0 0.05 +0.2 ± 4.4 0.04 
Trabecular area (mm2) 602.39 ± 90.72 -0.1 ± 0.5 0.4 +0.2 ± 0.6 0.04 
Trabecular vBMD (mgHA/cm3) 143.6 ± 40.1 +0.2 ± 4.2 0.8 -1.4 ± 6.4 0.6 
Trabecular number (mm-1) 1.61 ± 0.36 -1.1 ± 6.9 0.5 -1.0 ± 9.3 0.06 
Trabecular thickness (mm) 0.073 ± 0.011 +1.6 ± 7.1 0.4 -0.2 ± 9.2 0.05 
Trabecular separation (mm) 0.592 ± 0.244 +1.5 ± 7.1 0.4 +1.9 ± 9.8 0.06 
Trabecular inhomogeneity (mm-1) 0.33 ± 0.30 +1.4 ± 8.3 0.5 +3.2 ± 11.6 0.04 
Trabecular BV/TV (%) 11.96 ± 3.3 +0.3 ± 4.2 0.8 -1.4 ± 6.1 0.6 
Cortical area (mm2) 82.78 ± 15.56 +1.0 ± 6.5 0.6 -2.9 ± 8.6 0.006 
Cortical vBMD (mgHA/cm3) 787.4 ± 45.4 -0.8 ± 2.3 0.2 -3.4 ± 3.7 <0.0001 
Cortical thickness (mm) 0.80 ± 0.19 +0.8 ± 6.3 0.6 -3.1 ± 8.9 0.002 
Periosteal perimeter (mm) 110.65 ± 12.84 -0.5 ± 3.4 0.5 +0.5 ± 4.8 0.02 
Endocortical perimeter (mm) 99.86 ± 8.92 -1.6 ± 2.1 0.01 +0.6 ± 3.2 0.02 
Cortical porosity (%) 9.3 ± 1.9 +3.5 ± 10.4 0.2 +10.3 ± 17.5 0.0002 
Cortical TMD (mgHA/cm3) 947.4 ± 41.3 -1.4 ± 2.1 0.01 -3.8 ± 3.6 <0.0001 
Cortical pore diameter (mm) 0.193 ± 0.015 -0.6 ± 5.1 0.6 -1.6 ± 7.7 0.009 
Abbreviations: vBMD = volumetric bone mineral density, BV/TV = Bone volume/tissue volume, TMD = tissue 
mineral density 
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Figure legends 
 
Figure 1. A CONSORT diagram for the MOAT study. 
 
 
 
